All Insights Report Use Of Anti Arrhythmic Drugs Versus Ablation In Atrial Fibrillation (AFib) Report - Clinical And Economic Outcomes
Use Of Anti Arrhythmic Drugs Versus Ablation In Atrial Fibrillation (AFib) Report - Clinical And Economic Outcomes
Insights on anti Arrhythmic Drugs Vs Ablation in Atrial Fibrillation (AFib) report in Association of Clinical and Economic Outcomes & benefits.
![Use Of Anti Arrhythmic Drugs Versus Ablation In Atrial Fibrillation (AFib) Report - Clinical And Economic Outcomes](https://insights.axtria.com/hubfs/Axtria-2023/media-wall/Clinical-and-economic-outcomes-400x250.png)
Atrial Fibrillation (AFib) is associated with considerable morbidity and mortality and is characterized by arrhythmia, tachycardia, and/or bradycardia, and symptoms often include heart palpitations, shortness of breath, and weakness.
The objective of this study was to evaluate the economic benefits of anti-arrhythmic drugs (AADs) in comparison to ablation, both as individual treatments and as combination therapy with/ without considering the order of treatment. A Rhythm Control Economic model was used to compare different treatment scenarios assess the economic benefits of AADs (dronedarone, amiodarone, sotalol, flecainide, propafenone, dofetilide, and AADs as a group) vs ablation. The results of the study bring forward interesting insights in comparison of direct and combination therapies.
Contact us at connect@axtria.com with any questions.
Complete the brief form to download the white paper
Stay current on topics you care about
Recommended insights
![Anti Arrhythmic Drugs Vs Ablation in Atrial Fibrillation (AFib) Report](https://insights.axtria.com/hubfs/Risk%20Of%20Venous%20Thromboembolism%20And%20Major%20Bleeding%20In%20Patients%20With%20Acute%20Medical%20Illness%20Receiving%20Thromboprophylaxis%20With%20Enoxaparin.png)
Report